Analyse moyen terme - SARTORIUS STEDIM BIOTECH : La moyenne mobile, haussière, confirme notre avis.
Le précédent sommet vient d'être franchi, ceci confirme la tendance haussière. Le prochain objectif est à 102,90 €. Le niveau d'invalidation est sous 68,10 €.Arguments :
- La moyenne mobile, haussière, confirme notre avis.
- Le rectangle est déclenché, son objectif n'est pas encore atteint.
Sartorius Stedim Biotech is a provider of equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Co.'s solutions cover fermentation, filtration, purification, fluid management and lab technologies and membrane chromatography, including various conventional lab products to biopharmaceutical laboratories. Co.'s technologies, products and services are used to develop and manufacture medications and vaccines using biological methods. Co.'s products covers all upstream and downstream steps in the production of active pharmaceutical ingredients. It specializes in single-use products and offers technical consulting and services.
DayByDay is an independent research company providing global macro and single stock analysis, recommendation and allocation based purely on behavioural finance methods. Those include long term cycle analysis, sentiment analysis, and technical trigger. DayByDay serves all clients in need of practical and precise publications to make effective market decisions, on any time horizon, from a few hours to a few years.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.